| Storage Buffer | PBS pH 7.4 |
| Storage Temperature | -80ºC |
| Shipping Temperature | Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order. |
| Purification | Ion-exchange Purified |
| Cite This Product | Human Recombinant Beta Synuclein Monomers (StressMarq Biosciences | Victoria, BC CANADA | Catalog# SPR-405) |
| Certificate of Analysis | Certified >95% pure using SDS-PAGE analysis. Low endotoxin <5 EU/mL @ 2mg/mL. |
| Other Relevant Information | For corresponding PFFs, see catalog# SPR-457 |
| Alternative Names | Beta-synuclein, Synuclein beta, SNCB, SYUB_HUMAN, PNP14, Phosphoneuroprotein 14, 14 kDa brain-specific, G Protein Beta1/Gamma2 Subunit-Interacting Factor 1 |
| Research Areas | Alzheimer's Disease, Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein, Tangles & Tau |
| Cellular Localization | Cytoplasm |
| Accession Number | NP_001001502.1 |
| Gene ID | 6620 |
| Swiss Prot | Q16143 |
| Scientific Background |
Beta-synuclein, a soluble neuronal protein encoded by the SNCB gene, is increasingly recognized for its pivotal role in neurodegenerative disease research. Unlike its aggregation-prone counterpart alpha-synuclein, beta-synuclein monomers exhibit neuroprotective properties and are less likely to form toxic fibrils. Recent studies highlight beta-synuclein’s involvement in synaptic plasticity, regulation of dopamine metabolism, and inhibition of neuronal apoptosis. [www.uniprot.org] In Alzheimer’s disease (AD) and Lewy body dementia (LBD), elevated beta-synuclein levels in cerebrospinal fluid (CSF) and serum correlate with synaptic degeneration and disease progression. Novel assays targeting distinct epitopes of beta-synuclein have demonstrated its diagnostic potential, distinguishing early-stage AD from mild cognitive impairment and dementia. Furthermore, beta-synuclein’s dynamic expression across disease stages positions it as a promising biomarker for staging and monitoring neurodegeneration. [jnnp.bmj.com] Mechanistically, beta-synuclein modulates the phase behavior of alpha-synuclein, delaying its transition into neurotoxic aggregates. This regulatory function suggests a protective role in maintaining synaptic integrity and preventing pathological protein aggregation. [jnnp.bmj.com] As research advances, beta-synuclein monomers are emerging not only as biomarkers but also as potential therapeutic targets. Their unique biochemical properties and disease-specific expression patterns underscore their relevance in precision medicine approaches for neurodegenerative disorders. |
| References |
1. www.alz.org/alzheimers-dementia/facts-figures 2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118. |
Reviews
There are no reviews yet.